T2I
SRNE

Turim 21 Investimentos’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Turim 21 Investimentos’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,500
Closed -$28K – 109
2020
Q3 		$28K Buy
+2,500
New +$22.9K 0.03% 49

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Turim 21 Investimentos's SRNE Position: Q4 2020 in Review

Turim 21 Investimentos sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2020, closing a stake of 2,500 shares — an estimated $28K sold.

Turim 21 Investimentos first reported a position in SRNE in Q3 2020 and held it in 1 quarter. The position peaked at $28K in Q3 2020. 219 funds tracked by Wall St. Rank hold SRNE as of Q4 2020.

  • Turim 21 Investimentos reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Turim 21 Investimentos sold 2,500 Sorrento Therapeutics, Inc. shares in Q4 2020, an estimated $28K.
  • Turim 21 Investimentos first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 1 quarter.
  • Turim 21 Investimentos's Sorrento Therapeutics, Inc. position peaked at $28K in Q3 2020.
  • 219 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2020.

Based on Turim 21 Investimentos's 13F filing for Q4 2020, filed 12 Feb 2021.